Haemonetics Co. (NYSE:HAE) Short Interest Down 6.4% in March

Haemonetics Co. (NYSE:HAE) was the recipient of a large decrease in short interest in March. As of March 31st, there was short interest totalling 2,040,000 shares, a decrease of 6.4% from the March 15th total of 2,180,000 shares. Currently, 4.1% of the company’s shares are sold short. Based on an average daily volume of 455,600 shares, the days-to-cover ratio is currently 4.5 days.

Institutional Investors Weigh In On Haemonetics

A number of hedge funds have recently added to or reduced their stakes in HAE. American Century Companies Inc. lifted its stake in Haemonetics by 163.5% in the first quarter. American Century Companies Inc. now owns 17,407 shares of the medical instruments supplier’s stock valued at $1,100,000 after buying an additional 10,802 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Haemonetics by 3.1% during the first quarter. PNC Financial Services Group Inc. now owns 12,802 shares of the medical instruments supplier’s stock valued at $809,000 after purchasing an additional 387 shares during the period. Bank of Montreal Can increased its holdings in shares of Haemonetics by 300.3% during the first quarter. Bank of Montreal Can now owns 33,039 shares of the medical instruments supplier’s stock valued at $2,033,000 after purchasing an additional 24,785 shares during the period. Rhumbline Advisers increased its holdings in shares of Haemonetics by 1.9% during the first quarter. Rhumbline Advisers now owns 148,770 shares of the medical instruments supplier’s stock valued at $9,405,000 after purchasing an additional 2,817 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in shares of Haemonetics by 10.6% during the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 18,732 shares of the medical instruments supplier’s stock valued at $1,184,000 after purchasing an additional 1,788 shares during the period. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Stock Performance

Shares of HAE opened at $84.88 on Thursday. The company has a debt-to-equity ratio of 0.91, a current ratio of 2.92 and a quick ratio of 1.76. The stock has a market capitalization of $4.31 billion, a PE ratio of 34.50, a price-to-earnings-growth ratio of 2.01 and a beta of 0.36. Haemonetics has a 12-month low of $70.74 and a 12-month high of $95.26. The business’s fifty day moving average price is $78.72 and its 200 day moving average price is $82.77.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.94 by $0.10. The company had revenue of $336.20 million for the quarter, compared to analysts’ expectations of $320.84 million. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. The firm’s quarterly revenue was up 10.1% compared to the same quarter last year. During the same period last year, the business posted $0.85 earnings per share. Equities research analysts forecast that Haemonetics will post 3.95 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on HAE shares. TheStreet downgraded shares of Haemonetics from a “b-” rating to a “c+” rating in a research report on Thursday, February 29th. StockNews.com cut Haemonetics from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, Barrington Research restated an “outperform” rating and set a $105.00 price objective on shares of Haemonetics in a research note on Friday, April 12th.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.